Filing Analysis
Harvard Bioscience reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders approved the election of directors, the ratification of Grant Thornton LLP as auditors, executive compensation, and amendments to the 2021 Incentive Plan and Employee Stock Purchase Plan.
🚩 Red Flags
- Proposal 5 (Amended and Restated 2021 Incentive Plan) showed a relatively high number of 'Against' votes (680,030) compared to 'For' votes (1,131,261), indicating some shareholder dissent regarding equity dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2021 Incentive Plan, increasing authorized shares for awards by 400,000 shares.
- As of December 31, 2025, 646,520 shares were available for future awards prior to this increase.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Two Class II Directors, John Duke and Katherine A. Eade, were elected for three-year terms.
- The amendment to the Employee Stock Purchase Plan (ESPP) was approved.
Harvard Bioscience, Inc. released an updated corporate slide presentation for May 2026 to be used in discussions with the investment community. The filing serves as a standard Regulation FD disclosure to provide business updates and summaries.
📋 Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure) on May 12, 2026.
- Exhibit 99.1 contains the corporate slide presentation dated May 2026.
- The presentation is intended for distribution at various industry and investment conferences.
- The report was signed by Mark Frost, the Chief Financial Officer.
Harvard Bioscience, Inc. reported its financial results for the first quarter of 2026 on May 12, 2026. The company issued a press release and hosted a conference call to discuss the performance for the period ended March 31, 2026.
📋 Key Facts
- Financial results for the three months ended March 31, 2026, were released.
- A conference call was held on May 12, 2026, at 8:00 AM ET.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Harvard Bioscience, Inc. filed a Current Report on Form 8-K to disclose an updated corporate slide presentation intended for use at upcoming industry and investor conferences in March 2026.
📋 Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The corporate slide presentation is dated March 2026 and is attached as Exhibit 99.1.
- The presentation provides updates and summaries of the company's business for the investment community.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Harvard Bioscience, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company hosted a conference call on March 12, 2026, to discuss the performance.
📋 Key Facts
- Announced financial results for the three and twelve months ended December 31, 2025
- Scheduled a conference call for March 12, 2026, at 8:00 AM ET
- The filing includes Exhibit 99.1, the press release detailing the financial results
Harvard Bioscience (HBIO) has formalized employment agreements for its CEO and newly permanent CFO, while confirming a 1:10 reverse stock split effective March 13, 2026. The CEO's new contract includes a $100,000 bonus contingent on the successful refinancing of the company's credit facility, suggesting recent financial restructuring.
🚩 Red Flags
- 1:10 reverse stock split effective March 13, 2026, typically indicating delisting risk or price maintenance issues.
- CEO bonus specifically tied to 'successful refinancing' of debt, highlighting recent liquidity or credit pressure.
- Significant post-split equity grants (75k and 30k units) may be highly dilutive given the company's micro-cap status.
📋 Key Facts
- CEO John Duke's base salary set at $515,000 with a $100,000 bonus for credit facility refinancing.
- Mark Frost appointed permanent CFO and Treasurer, effective March 6, 2026, with a $375,000 base salary.
- A 1:10 reverse stock split is confirmed for March 13, 2026.
- CEO and CFO target equity grants for 2026 are 75,000 and 30,000 RSUs respectively (post-split).
Harvard Bioscience stockholders approved a reverse stock split at a special meeting on March 6, 2026. The Board of Directors subsequently set a final ratio of 1-for-10, effective March 13, 2026, to reduce the outstanding share count.
🚩 Red Flags
- Reverse stock split (1-for-10 ratio) is a red flag escalator.
- Authorized shares remain at 80,000,000 despite the 90% reduction in outstanding shares, significantly increasing the potential for future dilution.
📋 Key Facts
- Stockholders approved a reverse split ratio range of 1-for-5 to 1-for-15.
- The Board finalized the ratio at 1-for-10.
- The split is effective at 4:30 p.m. ET on March 13, 2026.
- Outstanding shares will be reduced from approximately 44,179,894 to approximately 4,471,989.
- Authorized shares will remain at 80,000,000.
- Split-adjusted trading begins on March 16, 2026, under the existing symbol HBIO with a new CUSIP.